Seelos Therapeutics Inc SEEL
€0.30 €0.21 (41.16%) 1D
Last Updated: Nov 22, 12:00 AM·MUN
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Seelos Therapeutics Inc Stock Halal?
Shariah Compliance Analysis of SEEL Stock
Germany Health Care Nano Cap No. As of September 2026, Seelos Therapeutics Inc (SEEL) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Seelos Therapeutics Inc does not pass Musaffa's business and financial screening criteria.
Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 10 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
SEEL Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Seelos Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Seelos Therapeutics Inc (SEEL) Chart
Financial Metrics & Statements of Seelos Therapeutics Inc (SEEL)
FAQ's for Seelos Therapeutics Inc (SEEL)
- As of September 2026, Seelos Therapeutics Inc SEEL is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Seelos Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Seelos Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Seelos Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Seelos Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Seelos Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Seelos Therapeutics Inc (SEEL)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
